Liquidia Stock (NASDAQ:LQDA)
Previous Close
$65.25
52W Range
$11.85 - $72.49
50D Avg
$48.75
200D Avg
$35.84
Market Cap
$6.37B
Avg Vol (3M)
$1.46M
Beta
0.59
Div Yield
-
LQDA Company Profile
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.